Share This Page
Drug Price Trends for SORINE
✉ Email this page to a colleague
Average Pharmacy Cost for SORINE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SORINE 160 MG TABLET | 00245-0014-89 | 0.15353 | EACH | 2025-04-23 |
| SORINE 120 MG TABLET | 00245-0013-89 | 0.09565 | EACH | 2025-04-23 |
| SORINE 160 MG TABLET | 00245-0014-01 | 0.15353 | EACH | 2025-04-23 |
| SORINE 240 MG TABLET | 00245-0015-89 | 0.17334 | EACH | 2025-04-23 |
| SORINE 120 MG TABLET | 00245-0013-01 | 0.09565 | EACH | 2025-04-23 |
| SORINE 240 MG TABLET | 00245-0015-01 | 0.17334 | EACH | 2025-04-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for SORINE
Introduction
SORINE, also known by its generic name, ursodiol (or ursodeoxycholic acid), is a drug primarily used to treat gallstones and primary biliary cholangitis. It was first approved by the FDA in 1987 and has secured its position as a standard treatment in hepatobiliary diseases. This analysis examines the current market landscape, uncertainties, competitive environment, and future price projections for SORINE, considering evolving regulatory, clinical, and economic factors.
Market Landscape Overview
Current Therapeutic Use and Demand
URSODIOL’s primary applications include:
- Dissolution of cholesterol gallstones in patients who are unsuitable for surgery.
- Management of primary biliary cholangitis (PBC).
- Off-label uses in various liver and biliary conditions.
According to data from the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 10-15% of adults in the U.S. suffer from gallstones, with a subset eligible for medical dissolution therapy using ursodiol. Globally, this indication sustains a steady demand, especially in regions where surgical interventions are less accessible.
Market Size and Revenue Estimates
The global market for ursodiol was valued at approximately $200 million in 2022, driven mainly by North America, Europe, and select Asian countries. In the United States, sales approximate $150 million annually, with the rest distributed across European markets and emerging economies.
The market is characterized by:
- Consistent demand for well-established therapeutic agents.
- Limited competition primarily from generic formulations, with few branded alternatives.
- Off-label use as a significant factor impacting sales volumes.
Regulatory and Patent Landscape
URSODIOL’s patent protections have long expired; thus, generic options dominate. The absence of patent exclusivity encourages price competition but also limits premium pricing opportunities. Regulatory approvals are stable across major markets, facilitating ongoing market presence.
Competitive Environment
Generic Competition
Since the expiration of patents, generic ursodiol products have proliferated globally, notably reducing prices. Market entry barriers are low, amplifying price erosion, especially with manufacturers in India and China providing cost-effective alternatives.
Branded versus Generic Dynamics
Despite intense generic competition, there remains a niche for branded formulations, often distinguished by manufacturing quality, formulation enhancements, or packaging. However, price premiums over generics are minimal, typically 5-10%.
Market Penetration and Patient Access
The widespread availability of generics fosters high accessibility but also pressure on pricing. Insurance coverage varies, with payers often favoring lower-cost generics, further constraining potential for price hikes.
Regulatory and Clinical Trends
Emerging Clinical Data
Recent clinical research underscores the importance of ursodiol in managing cholestatic liver disease, potentially expanding its therapeutic scope. However, evidence supporting significant new indications remains limited, thus unlikely to impact market size dramatically in the near term.
Regulatory Changes
Regulatory environments for generic drugs are increasingly stringent regarding bioequivalence and manufacturing standards, potentially influencing costs and supply stability but are unlikely to restrict market access significantly.
Price Projections and Future Outlook
Factors Influencing Price Trends
- Market Saturation: Near-full generic competition limits ability for significant price increases.
- Manufacturing Costs: Advancements in cost efficiencies and manufacturing compliance could marginally influence prices.
- Regulatory Developments: New formulations or delivery systems (e.g., extended-release) could command higher prices but are unlikely to dominate before competition catches up.
- Market Penetration: Increasing adoption in emerging markets coincides with potential for price stabilization but not appreciable increases.
Projected Price Trajectory (Next 5 Years)
Given the market conditions, no substantial price increases are anticipated. Minor fluctuations are expected due to inflation, manufacturing cost shifts, and market dynamics:
| Year | Estimated Price per Unit (Average) | Rationale |
|---|---|---|
| 2023 | ~$0.10 - $0.15 | Stable generic market, slight cost pressures |
| 2024 | ~$0.10 - $0.15 | Continuation of current pricing, no major shifts |
| 2025 | ~$0.09 - $0.14 | Slight downward trend from intense competition |
| 2026 | ~$0.09 - $0.14 | Market saturation persists, pricing stabilizes |
| 2027 | ~$0.09 - $0.14 | Marginal corrections, sustained generic competition |
Note: These estimates are in line with historical pricing trends for approved, patent-expired drugs in the hepatobiliary segment.
Implications for Stakeholders
- Pharmaceutical Manufacturers: Limited scope for premium pricing; focus on manufacturing efficiencies and supply chain stability.
- Investors: Expect stable, low-margin returns due to intense price competition.
- Healthcare Providers and Payers: Favor generic options; potential for cost savings in treatment.
- Regulatory Bodies: Continued emphasis on manufacturing standards ensures supply and quality without affecting pricing significantly.
Key Takeaways
- The SORINE market is mature, with an established position as a generic ursodiol product across global markets.
- Price competition remains fierce, limiting opportunities for significant price hikes.
- Market growth is primarily driven by increasing prevalence of gallstone disease and expanding indications within hepatology.
- Future pricing trends are expected to remain stable or slightly decline, reflecting ongoing generic competition.
- Strategic factors such as formulation innovations or indication extension are unlikely to alter the current pricing trajectory significantly.
Frequently Asked Questions
1. Will the price of SORINE increase if new indications are approved?
Unlikely. Although new indications could expand demand, manufacturers won't typically increase prices due to competition from generics. Any price adjustments would be moderate and justified by clinical benefits.
2. How does patent expiration affect SORINE’s market value?
Patent expiration has opened the market to generic competition, significantly reducing prices and margins, aligning the market with typical generic drug dynamics.
3. Are there opportunities for branded SORINE formulations to command higher prices?
Limited. The active ingredient is off-patent, and brand differentiation may appeal to specific niches but seldom results in substantial price premiums.
4. What are the major risks to the stable pricing of SORINE?
Market entry by new competitors, changes in healthcare policies favoring generics, potential supply chain disruptions, and regulatory shifts could influence prices either downward or upward.
5. Is there potential for SORINE to diversify into new therapeutic areas?
While research suggests possible additional uses, current evidence is insufficient to expand beyond established indications. Any diversification would depend on future clinical and regulatory developments.
References
[1] National Institute of Diabetes and Digestive and Kidney Diseases. Gallstones. (2022).
[2] IQVIA. Global Pharmaceutical Market Trends. (2022).
[3] European Medicines Agency. Ursodiol (2018).
[4] FDA. Food and Drug Administration. Drug Approvals and Market Data. (2022).
[5] MarketWatch. Hepatology Drugs Market Analysis. (2022).
More… ↓
